To our knowledge, a single-phase III trial evaluated 197 premenopausal ER+ HER2 negative breast cancer patients in Japan to receive anastrazole or tamoxifen plus goserelin for 24 weeks before surgery. The gene discussed is ERBB2; the disease is breast cancer.